Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study

This open-label, two-way, crossover, phase Ib drug–drug interaction study investigated whether the pharmacokinetics (PKs) and safety profile of lurbinectedin (LRB) are affected by co-administration of a moderate CYP3A4 inducer (bosentan, BOS) in adult patients with advanced solid tumors. Eleven pati...

Full description

Bibliographic Details
Main Authors: Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Cristian Fernández, Jorge Luis Iglesias, Gema Corral, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Pharmaceuticals
Subjects:
drug–drug interaction
CYP3A4
bosentan
pharmacokinetics
lurbinectedin
cancer patients
Online Access:https://www.mdpi.com/1424-8247/17/2/182

Internet

https://www.mdpi.com/1424-8247/17/2/182

Similar Items